vs

Side-by-side financial comparison of CREATIVE REALITIES, INC. (CREX) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

CREATIVE REALITIES, INC. is the larger business by last-quarter revenue ($23.9M vs $13.7M, roughly 1.7× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -8.2%, a 83.9% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-4.6M).

Creative Realities, Inc. is a provider of end-to-end immersive digital experience solutions, including interactive digital signage, content management software, and custom experiential design services. It primarily caters to retail, hospitality, healthcare, corporate workplace, and public sector clients across North America, helping brands enhance customer engagement and operational efficiency.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

CREX vs XLO — Head-to-Head

Bigger by revenue
CREX
CREX
1.7× larger
CREX
$23.9M
$13.7M
XLO
Higher net margin
XLO
XLO
83.9% more per $
XLO
75.7%
-8.2%
CREX
More free cash flow
XLO
XLO
$2.5M more FCF
XLO
$-2.1M
$-4.6M
CREX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CREX
CREX
XLO
XLO
Revenue
$23.9M
$13.7M
Net Profit
$-2.0M
$10.4M
Gross Margin
47.9%
Operating Margin
1.9%
-86.5%
Net Margin
-8.2%
75.7%
Revenue YoY
117.2%
Net Profit YoY
30.8%
179.1%
EPS (diluted)
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CREX
CREX
XLO
XLO
Q4 25
$23.9M
$13.7M
Q3 25
$10.5M
$19.1M
Q2 25
$13.0M
$8.1M
Q1 25
$9.7M
$2.9M
Q4 24
$11.0M
Q3 24
$14.4M
Q2 24
$13.1M
Q1 24
$12.3M
Net Profit
CREX
CREX
XLO
XLO
Q4 25
$-2.0M
$10.4M
Q3 25
$-7.9M
$-16.3M
Q2 25
$-1.8M
$-15.8M
Q1 25
$3.4M
$-13.3M
Q4 24
$-2.8M
Q3 24
$54.0K
Q2 24
$-615.0K
Q1 24
$-109.0K
Gross Margin
CREX
CREX
XLO
XLO
Q4 25
47.9%
Q3 25
45.3%
Q2 25
38.5%
Q1 25
45.7%
Q4 24
44.2%
Q3 24
45.6%
Q2 24
51.8%
Q1 24
46.9%
Operating Margin
CREX
CREX
XLO
XLO
Q4 25
1.9%
-86.5%
Q3 25
-68.9%
-10.1%
Q2 25
-10.2%
-177.7%
Q1 25
-7.4%
-472.7%
Q4 24
-6.5%
Q3 24
7.9%
Q2 24
4.5%
Q1 24
-0.6%
Net Margin
CREX
CREX
XLO
XLO
Q4 25
-8.2%
75.7%
Q3 25
-74.5%
-85.4%
Q2 25
-13.9%
-196.0%
Q1 25
34.6%
-452.7%
Q4 24
-25.8%
Q3 24
0.4%
Q2 24
-4.7%
Q1 24
-0.9%
EPS (diluted)
CREX
CREX
XLO
XLO
Q4 25
$-3.74
Q3 25
$-0.75
$-0.11
Q2 25
$-0.17
$-0.16
Q1 25
$0.32
$-0.18
Q4 24
$-0.28
Q3 24
$0.01
Q2 24
$-0.06
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CREX
CREX
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$1.6M
$137.5M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$21.5M
$35.3M
Total Assets
$151.0M
$154.7M
Debt / EquityLower = less leverage
2.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CREX
CREX
XLO
XLO
Q4 25
$1.6M
$137.5M
Q3 25
$314.0K
$103.8M
Q2 25
$569.0K
$121.6M
Q1 25
$1.1M
$89.1M
Q4 24
$1.0M
Q3 24
$868.0K
Q2 24
$4.1M
Q1 24
$2.9M
Total Debt
CREX
CREX
XLO
XLO
Q4 25
$44.0M
Q3 25
$22.0M
Q2 25
$19.9M
Q1 25
$23.0M
Q4 24
$13.0M
Q3 24
$10.7M
Q2 24
$13.6M
Q1 24
$12.8M
Stockholders' Equity
CREX
CREX
XLO
XLO
Q4 25
$21.5M
$35.3M
Q3 25
$21.9M
$-8.1M
Q2 25
$29.4M
$7.1M
Q1 25
$29.9M
$10.7M
Q4 24
$25.5M
Q3 24
$28.3M
Q2 24
$28.2M
Q1 24
$28.8M
Total Assets
CREX
CREX
XLO
XLO
Q4 25
$151.0M
$154.7M
Q3 25
$61.3M
$133.7M
Q2 25
$63.7M
$133.8M
Q1 25
$67.0M
$103.7M
Q4 24
$65.2M
Q3 24
$67.6M
Q2 24
$69.6M
Q1 24
$68.2M
Debt / Equity
CREX
CREX
XLO
XLO
Q4 25
2.04×
Q3 25
1.00×
Q2 25
0.68×
Q1 25
0.77×
Q4 24
0.51×
Q3 24
0.38×
Q2 24
0.48×
Q1 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CREX
CREX
XLO
XLO
Operating Cash FlowLast quarter
$-4.5M
$-2.0M
Free Cash FlowOCF − Capex
$-4.6M
$-2.1M
FCF MarginFCF / Revenue
-19.1%
-15.3%
Capex IntensityCapex / Revenue
0.4%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CREX
CREX
XLO
XLO
Q4 25
$-4.5M
$-2.0M
Q3 25
$-1.6M
$-17.5M
Q2 25
$773.0K
$-14.5M
Q1 25
$-2.4M
$29.0M
Q4 24
$-1.4M
Q3 24
$544.0K
Q2 24
$2.3M
Q1 24
$1.9M
Free Cash Flow
CREX
CREX
XLO
XLO
Q4 25
$-4.6M
$-2.1M
Q3 25
$-1.7M
Q2 25
$672.0K
$-14.9M
Q1 25
$-2.5M
$29.0M
Q4 24
$-1.4M
Q3 24
$543.0K
Q2 24
$2.3M
Q1 24
$1.9M
FCF Margin
CREX
CREX
XLO
XLO
Q4 25
-19.1%
-15.3%
Q3 25
-16.2%
Q2 25
5.2%
-184.0%
Q1 25
-25.2%
988.3%
Q4 24
-12.5%
Q3 24
3.8%
Q2 24
17.3%
Q1 24
15.7%
Capex Intensity
CREX
CREX
XLO
XLO
Q4 25
0.4%
0.7%
Q3 25
1.0%
0.0%
Q2 25
0.8%
5.0%
Q1 25
0.1%
0.8%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CREX
CREX
XLO
XLO
Q4 25
-0.19×
Q3 25
Q2 25
Q1 25
-0.73×
Q4 24
Q3 24
10.07×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CREX
CREX

Service And Other$17.3M72%
Managed Services$4.7M20%
Installation Services$1.7M7%

XLO
XLO

Segment breakdown not available.

Related Comparisons